Impact of rituximab on relapse rate and disability in neuromyelitis optica

Multiple Sclerosis Journal

Volumn 17, Issue 10, 2011, Pages 1225-1230

  Bedi, Gurdesh S ^a   Brown, Andrew D ^a   Delgado, Sylvia R ^a   Usmani, Nida ^a   Lam, Byron L ^a   Sheremata, William A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CD19 20; disease modifying therapies; immune suppressant; monoclonal antibody; neuromyelitis optica; rituximab

Indexed keywords

AQUAPORIN 4; AZATHIOPRINE; CD20 ANTIGEN; DIPHENHYDRAMINE; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; DEMYELINATING DISEASE; DISABILITY; DRUG USE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MYELOOPTIC NEUROPATHY; PATHOGENESIS; RECURRENCE RISK; TREATMENT OUTCOME;

EID: 80053583158     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511404586     Document Type: Article

References (17)

1. Devic E. Myelite subaigue compliquee de nevrite optique. Bull Med. 1894 ; 8: 1033-1034
2. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002 ; 125: 1450-1461 (Pubitemid 34755161)
3. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489 (Pubitemid 43958540)
4. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 ; 364 (9451). 2106-2112 (Pubitemid 39626806)
5. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998 ; 51: 1219-1220 (Pubitemid 28473439)
6. Minagar A, Sheremata WA. Treatment of Devic's disease with methotrexate and prednisone. Int J MS Care. 2000 ; 2: 6-15
7. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006 ; 63: 957-963 (Pubitemid 44036296)
8. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci. 2007 ; 252: 57-61 (Pubitemid 44909191)
9. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis treatment: analysis of 36 patients. Arch Neurol. 2010 ; 67: 1131-1136
10. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009 ; 66: 1128-1133
11. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010 ; 17 (8). 1019-1032
12. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005 ; 64: 1270-1272
13. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008 ; 20: 444-449
14. Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci. 2007 ; 28: 209-211 (Pubitemid 47263843)
15. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008 ; 65: 1443-1448
16. Vaknin-Dembinsky A, Brill L, Orpaz N, Abramsky O, Karussis D. Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population. Mult Scler. 2010 ; 16 (12). 1453-1457
17. Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 2010 ; 3 (2). 93-105